A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants

NCT06937411 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
88
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Eli Lilly and Company